SCHEMBL85992

SCHEMBL85992

NC(=O)CC1=Nc2ccccc2C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.42
NOS1 P29475 1/20 0.42
NOS2 P35228 1/20 0.42
TRPA1 O75762 5/20 0.39
SIGMAR1 Q99720 1/20 0.37
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CYP2D6 P10635 1/20 0.35
RECQL P46063 1/20 0.35
HRH1 P35367 3/20 0.34
HTR2A P28223 2/20 0.34
HRH4 Q9H3N8 1/20 0.33
CA2 P00918 1/20 0.32
RARA P10276 1/20 0.32
RARB P10826 1/20 0.32
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32
LMNA P02545 1/20 0.32
NPC1 O15118 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9938378 0.85 NOS3 (0.53) NOS3NOS1NOS2TRPA1SIGMAR1
SCHEMBL8021974 0.84 AKR1B1 (0.41) NOS3NOS1NOS2TRPA1SIGMAR1
SCHEMBL11048325 0.83 ALDH1A1 (0.41) NOS3NOS1NOS2TRPA1SIGMAR1
SCHEMBL5833897 0.76 NOS3 (0.44) NOS3NOS1NOS2TRPA1SIGMAR1
SCHEMBL11563083 0.76 NOS3 (0.39) NOS3NOS1NOS2TRPA1SIGMAR1
SCHEMBL27008239 0.73 NOS3 (0.50) NOS3NOS1NOS2TRPA1SIGMAR1
SCHEMBL20581797 0.73 TRPA1 (0.40) NOS3NOS1NOS2TRPA1SIGMAR1
SCHEMBL28159999 0.72 ALDH1A1 (0.46) NOS3NOS1NOS2TRPA1HRH1
SCHEMBL11564654 0.72 NOS3 (0.35) NOS3NOS1NOS2TRPA1SIGMAR1
SCHEMBL11565601 0.72 NOS3 (0.39) NOS3NOS1NOS2TRPA1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129396-B2 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors TELIK, INC. (US) 2012-03-06 US disclosed
US-20100081653-A1 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors TELIK, INC. 2010-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081653-A1 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors MAP3K2, MAP4K2, MAP3K12 NOS3 3188/4885NOS1 3608/4885NOS2 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.